Literature DB >> 25877553

Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.

Wenfang Li1, Ling Ye1, Ricardo Carrion2, Gopi S Mohan1, Jerritt Nunneley2, Hilary Staples2, Anysha Ticer2, Jean L Patterson2, Richard W Compans1, Chinglai Yang1.   

Abstract

In addition to its surface glycoprotein (GP), Ebola virus directs the production of large quantities of a truncated glycoprotein isoform (sGP) that is secreted into the extracellular space. We recently reported that sGP actively diverts host antibody responses against the epitopes that it shares with GP and thereby allows itself to absorb anti-GP antibodies, a phenomenon we termed "antigenic subversion." To investigate the effect of antigenic subversion by sGP on protection against virus infection, we compared immune responses induced by different prime-boost immunization regimens with GP and sGP DNA vaccines in mice and their efficacy against lethal Ebola virus challenge. Similar levels of anti-GP antibodies were induced by 2 immunizations with sGP and GP DNA vaccines. However, 2 immunizations with GP but not sGP DNA vaccine fully protected mice from lethal challenge. Boosting with sGP or GP DNA vaccine in mice that had been primed by GP or sGP DNA vaccine augmented the levels of anti-GP antibody responses and further improved protective efficacy against Ebola virus infection. These results show that both the quality and the levels of anti-GP antibody responses affect the efficacy of protection against Ebola virus infection.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Ebola; antigenic subversion; soluble GP; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25877553      PMCID: PMC4564543          DOI: 10.1093/infdis/jiv186

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.

Authors:  Xiangguo Qiu; Jonathan Audet; Gary Wong; Stephane Pillet; Alexander Bello; Teresa Cabral; Jim E Strong; Frank Plummer; Cindy R Corbett; Judie B Alimonti; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

2.  A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Authors:  Julie E Martin; Nancy J Sullivan; Mary E Enama; Ingelise J Gordon; Mario Roederer; Richard A Koup; Robert T Bailer; Bimal K Chakrabarti; Michael A Bailey; Phillip L Gomez; Charla A Andrews; Zoe Moodie; Lin Gu; Judith A Stein; Gary J Nabel; Barney S Graham
Journal:  Clin Vaccine Immunol       Date:  2006-09-20

3.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

4.  Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Authors:  Andrea Marzi; Flora Engelmann; Friederike Feldmann; Kristen Haberthur; W Lesley Shupert; Douglas Brining; Dana P Scott; Thomas W Geisbert; Yoshihiro Kawaoka; Michael G Katze; Heinz Feldmann; Ilhem Messaoudi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

5.  Ebola virus-like particles protect from lethal Ebola virus infection.

Authors:  Kelly L Warfield; Catharine M Bosio; Brent C Welcher; Emily M Deal; Mansour Mohamadzadeh; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

6.  Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Authors:  Andrew S Herbert; Ana I Kuehne; James F Barth; Ramon A Ortiz; Donald K Nichols; Samantha E Zak; Spencer W Stonier; Majidat A Muhammad; Russell R Bakken; Laura I Prugar; Gene G Olinger; Jennifer L Groebner; John S Lee; William D Pratt; Max Custer; Kurt I Kamrud; Jonathan F Smith; Mary Kate Hart; John M Dye
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

7.  Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.

Authors:  Gary Wong; Jason S Richardson; Stéphane Pillet; Ami Patel; Xiangguo Qiu; Judie Alimonti; Jeff Hogan; Yi Zhang; Ayato Takada; Heinz Feldmann; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2012-10-31       Impact factor: 17.956

8.  Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Authors:  Gopi S Mohan; Wenfang Li; Ling Ye; Richard W Compans; Chinglai Yang
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

9.  Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells.

Authors:  Reed S Shabman; Omar J Jabado; Chad E Mire; Timothy B Stockwell; Megan Edwards; Milind Mahajan; Thomas W Geisbert; Christopher F Basler
Journal:  MBio       Date:  2014-11-04       Impact factor: 7.867

10.  Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Authors:  Joseph E Blaney; Andrea Marzi; Mallory Willet; Amy B Papaneri; Christoph Wirblich; Friederike Feldmann; Michael Holbrook; Peter Jahrling; Heinz Feldmann; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

View more
  10 in total

Review 1.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

2.  Expression of Clonorchis sinensis GIIIsPLA2 protein in baculovirus-infected insect cells and its overexpression facilitating epithelial-mesenchymal transition in Huh7 cells via AKT pathway.

Authors:  Mei Shang; Zhizhi Xie; Zeli Tang; Lei He; Xiaoyun Wang; Caiqin Wang; Yinjuan Wu; Ye Li; Lu Zhao; Zhiyue Lv; Zhongdao Wu; Yan Huang; Xinbing Yu; Xuerong Li
Journal:  Parasitol Res       Date:  2017-02-20       Impact factor: 2.289

3.  Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.

Authors:  Ying Liu; Ling Ye; Fang Lin; Yasmine Gomaa; David Flyer; Ricardo Carrion; Jean L Patterson; Mark R Prausnitz; Gale Smith; Gregory Glenn; Hua Wu; Richard W Compans; Chinglai Yang
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

4.  Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations.

Authors:  Lisa H Cazares; Michael D Ward; Ernst E Brueggemann; Tara Kenny; Paul Demond; Christopher R Mahone; Karen A O Martins; Jonathan E Nuss; Trevor Glaros; Sina Bavari
Journal:  Clin Proteomics       Date:  2016-09-05       Impact factor: 3.988

5.  Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.

Authors:  Oleg V Pyankov; Yin Xiang Setoh; Sergey A Bodnev; Judith H Edmonds; Olga G Pyankova; Stepan A Pyankov; Gabor Pali; Shane Belford; Louis Lu; Mylinh La; George Lovrecz; Valentina A Volchkova; Keith J Chappell; Daniel Watterson; Glenn Marsh; Paul R Young; Alexander A Agafonov; Jillann F Farmer; Victor E Volchkov; Andreas Suhrbier; Alexander A Khromykh
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

6.  An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.

Authors:  Yupeng Feng; Chufang Li; Peiyu Hu; Qian Wang; Xuehua Zheng; Yongkun Zhao; Yi Shi; Songtao Yang; Changhua Yi; Ying Feng; Chunxiu Wu; Linbing Qu; Wei Xu; Yao Li; Caijun Sun; Fu Geroge Gao; Xianzhu Xia; Liqiang Feng; Ling Chen
Journal:  Emerg Microbes Infect       Date:  2018-06-06       Impact factor: 7.163

Review 7.  Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections.

Authors:  Sai Priya Anand; Andrés Finzi
Journal:  Vaccines (Basel)       Date:  2019-08-30

8.  Porcine IL-12 plasmid as an adjuvant improves the cellular and humoral immune responses of DNA vaccine targeting transmissible gastroenteritis virus spike gene in a mouse model.

Authors:  Xunliang Li; Pengchong Li; Liyan Cao; Yunyun Bai; Huijie Chen; He Liu; Xiaofeng Ren; Guangxing Li
Journal:  J Vet Med Sci       Date:  2019-09-02       Impact factor: 1.267

9.  Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge.

Authors:  Ying Liu; Ling Ye; Fang Lin; Yasmine Gomaa; David Flyer; Ricardo Carrion; Jean L Patterson; Mark R Prausnitz; Gale Smith; Gregory Glenn; Hua Wu; Richard W Compans; Chinglai Yang
Journal:  Sci Rep       Date:  2018-07-25       Impact factor: 4.379

10.  Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.

Authors:  Samira Locher; Marc Schweneker; Jürgen Hausmann; Gert Zimmer
Journal:  J Gen Virol       Date:  2018-06-05       Impact factor: 3.891

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.